Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist
– Transenteric delivery of incretin triagonist of GLP-1, GIP, glucagon receptors elicits rapid weight loss in animal study –
– Preclinical data support the potential for the RaniPill platform to enable oral delivery of multiple obesity treatments –
Related news for (RANI)
- Today’s Top Performers: MoBot’s Market Review 10/22/25 09:00 AM
- MoBot’s Stock Market Highlights – 10/22/25 06:00 AM
- Breaking News: MoBot’s Latest Update as of 10/22/25 05:00 AM
- Biotech Breakthroughs, Trans Snack Surges & a Spider Silk Revolution Power Small-Cap Rally
- MoBot alert highlights: NASDAQ: BYND, NASDAQ: ADVB, NASDAQ: NAUT, NASDAQ: RANI, NASDAQ: VELO (10/21/25 12:00 PM)